Last reviewed · How we verify
NOAC: Lixiana
At a glance
| Generic name | NOAC: Lixiana |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy (PHASE4)
- Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study
- Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (PHASE3)
- PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation (PHASE3)
- Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants
- Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)
- MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention (PHASE3)
- Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NOAC: Lixiana CI brief — competitive landscape report
- NOAC: Lixiana updates RSS · CI watch RSS
- Bayer portfolio CI